CTIS2023-508683-30-00招募中1 期
A Registry-Based Extension of Protocol V503-001 in Countries with Centralized Cervical Cancer Screening Infrastructures to Evaluate the Long-Term Effectiveness, immunogenicity, and Safety of Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine as Administered to 16- to 26- Year- Old Women. - V503-021
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 376
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •Randomized into the V503-001 (NCT00543543) study from a Denmark, Norway, or Sweden site and participated in the study by receiving either the selected dose formulation of the 9vHPV vaccine or GARDASIL, Agrees to allow passive follow-up, analysis of biopsy specimens, future contact from the National Registry Study Centers, and serum collection
排除标准
- •There are no exclusion criteria
研究者
相似试验
进行中（未招募）
不适用
Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)Genital WartsCervical CancerVulvar CancerHuman Papillomavirus InfectionVaginal CancerNCT02653118Merck Sharp & Dohme LLC4,453
已完成
不适用
Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma-C64 Malignant neoplasm of kidney, except renal pelvisMalignant neoplasm of kidney, except renal pelvisC64PER-019-06PFIZER S.A.,
已完成
3 期
Protocol EFC16293: A Phase 3 Open-Label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc von Willebrand Factor XTEN Fusion Protein (rFVIIIFc VWF XTEN; BIVV001) in Previously Treated Patients *12 Years of Age With Severe Hemophilia A.NL-OMON54973Sanofi-aventis3
进行中（未招募）
1 期
Extension E-03 al Protocolo nº RAD001AB253Estudio de seguimiento de 2 años para obtener datos especificos de la evolución de los pacientes de novo trasplantados cardíacos que discontinuaron la medicación de estudio de forma precoz en el estudio RAD001AB253Extension E-03 to Protocol No. RAD001A B253Tiene también en cuenta la Enmienda nº1 al Protocolo RAD001B253E3Trasplante cardiaco de novoEUCTR2005-004908-36-ESovartis Farmaceútica S.A
进行中（未招募）
1 期
An extension study to enable patients to continue to receive Guanfacine Hydrocloride Extended Release tablets after completing either study SPD503-315 or SPD503-316.Attention Deficit/Hyperactivity Disorder (ADHD)MedDRA version: 17.0Level: LLTClassification code 10064104Term: ADHDSystem Organ Class: 100000004873EUCTR2011-004668-31-GBShire Pharmaceutical Development Ltd249